-
K287859-10mgProduct Describtion:KML29 is an extremely selective, orally active and irreversible inhibitor of MAGL with IC50 of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively.
-
K287859-25mgProduct Describtion:KML29 is an extremely selective, orally active and irreversible inhibitor of MAGL with IC50 of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively.
-
K287859-50mgProduct Describtion:KML29 is an extremely selective, orally active and irreversible inhibitor of MAGL with IC50 of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively.
-
K287859-5mgProduct Describtion:KML29 is an extremely selective, orally active and irreversible inhibitor of MAGL with IC50 of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively.
-
K287624-100mgPotent Ack1 and ALK dual inhibitor.
-
K287624-10mgPotent Ack1 and ALK dual inhibitor.
-
K287624-25mgPotent Ack1 and ALK dual inhibitor.
-
K287624-50mgPotent Ack1 and ALK dual inhibitor.
-
K301871-100mlKrebs-Ringer HEPES(KRH) Buffered Solution.
-
Ab176659-100μgKRN330 (anti-GPA33) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities.Purity>:95%
-
Ab176659-10mgKRN330 (anti-GPA33) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities.Purity>:95%
-
Ab176659-1mgKRN330 (anti-GPA33) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities.Purity>:95%